Edwards Lifesciences (EW) to Restate Financial Statements for First Three Quarters of 2011
Tweet
Share
E-mailGet Alerts EW Hot Sheet
Price: $89.79 -0.04%
Financial Fact:
Selling, general and administrative expenses: 229.6M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Selling, general and administrative expenses: 229.6M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
In a Form 8-K Monday afternoon, Edwards Lifesciences (NYSE: EW) concluded that the Company’s previously issued financial statements for the first three quarters of 2011 should be restated due to certain technical errors in the balance sheets and cash flow statements for these interim periods. These errors related to (1) the classification between cash and cash equivalents and short-term investments, and (2) the treatment of excess tax benefit from stock plans. Consequently, the previously issued financial statements for each of the first three quarters of 2011 should no longer be relied upon.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- enVVeno Medical (NVNO) files $100M mixed shelf
- Cytek faces $56M damages award in Beckman Coulter patent case
Create E-mail Alert Related Categories
Corporate News, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
